
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Neuronetics Inc (STIM)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: STIM (4-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6.5
1 Year Target Price $6.5
1 | Strong Buy |
2 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 164.87% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.64M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 4 | Beta 1.28 | 52 Weeks Range 0.52 - 5.92 | Updated Date 09/14/2025 |
52 Weeks Range 0.52 - 5.92 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -43.92% | Operating Margin (TTM) -21.15% |
Management Effectiveness
Return on Assets (TTM) -20.34% | Return on Equity (TTM) -190.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 276152062 | Price to Sales(TTM) 1.86 |
Enterprise Value 276152062 | Price to Sales(TTM) 1.86 | ||
Enterprise Value to Revenue 2.49 | Enterprise Value to EBITDA -2.02 | Shares Outstanding 66124800 | Shares Floating 40965648 |
Shares Outstanding 66124800 | Shares Floating 40965648 | ||
Percent Insiders 9.44 | Percent Institutions 59.08 |
Upturn AI SWOT
Neuronetics Inc

Company Overview
History and Background
Neuronetics, Inc. was founded in 2003. It is a medical technology company focused on developing and commercializing innovative, non-invasive neurostimulation therapies for patients suffering from neurological and psychiatric disorders. The company's primary focus has been on Transcranial Magnetic Stimulation (TMS) for the treatment of depression.
Core Business Areas
- NeuroStar TMS Therapy System: Develops, manufactures, and markets the NeuroStar Advanced Therapy System, which delivers TMS therapy for the treatment of major depressive disorder (MDD).
- Service and Support: Provides ongoing service, support, and training to clinics utilizing the NeuroStar system.
Leadership and Structure
The leadership team typically includes a CEO, CFO, CMO, and other key executives. The organizational structure is hierarchical, with departments focused on research and development, manufacturing, sales and marketing, and clinical support.
Top Products and Market Share
Key Offerings
- NeuroStar TMS Therapy System: NeuroStar is Neuronetics' primary product, a TMS system used to treat Major Depressive Disorder (MDD). While precise market share figures are difficult to obtain, Neuronetics is a significant player in the TMS therapy market. Competitors include Brainsway (BWAY), MagVenture, and CloudTMS. Reimbursement rates and clinical efficacy data drive adoption. Revenue is derived from system sales, per-procedure revenue, and service contracts.
Market Dynamics
Industry Overview
The neuromodulation market is growing, driven by an increasing prevalence of depression and a desire for non-pharmacological treatment options. TMS therapy is gaining acceptance as a viable alternative or adjunct to antidepressants.
Positioning
Neuronetics positions itself as a leading provider of TMS therapy for depression. Its competitive advantages include established brand recognition, clinical data supporting NeuroStar's efficacy, and a network of trained clinicians.
Total Addressable Market (TAM)
The TAM for depression treatment is substantial, encompassing millions of individuals. Neuronetics is positioned to capture a portion of this market through TMS therapy, with growth dependent on increasing awareness, adoption, and reimbursement coverage.
Upturn SWOT Analysis
Strengths
- Established brand recognition in TMS
- FDA clearance for NeuroStar
- Extensive clinical data supporting efficacy
- Large installed base of NeuroStar systems
Weaknesses
- Limited product portfolio (primarily focused on TMS for depression)
- Relatively high cost of TMS therapy
- Dependence on reimbursement rates
- Ongoing losses and need for financing
Opportunities
- Expansion of TMS therapy into new indications (e.g., anxiety, OCD)
- Development of next-generation TMS technology
- Increased adoption of TMS therapy by psychiatrists and primary care physicians
- Partnerships with mental health providers
Threats
- Competition from other TMS systems and neuromodulation therapies
- Changes in reimbursement policies
- Negative publicity or safety concerns related to TMS
- Economic downturn affecting patient affordability
Competitors and Market Share
Key Competitors
- BWAY
- None
Competitive Landscape
Neuronetics faces competition from other TMS system manufacturers. The landscape is shaped by factors such as clinical efficacy, ease of use, cost, and reimbursement coverage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on the adoption rates of NeuroStar TMS. Recent growth may have been tempered.
Future Projections: Future growth projections depend on factors like increasing TMS therapy adoption, new indications, and improvements in reimbursement.
Recent Initiatives: Recent initiatives include efforts to expand the use of NeuroStar in new settings, develop new marketing programs, and secure favorable reimbursement coverage.
Summary
Neuronetics, Inc. focuses on TMS therapy, primarily for depression. While they have an established brand, their growth depends on expanding adoption and securing favorable reimbursement. They face competition from other TMS providers and rely on future growth initiatives. Overall, the company is moderately strong, excelling in established TMS tech but needs diversification.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neuronetics Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is approximate and subject to change. Financial data should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuronetics Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2018-06-28 | President, CEO & Director Mr. Keith J. Sullivan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 716 | Website https://neurostar.com |
Full time employees 716 | Website https://neurostar.com |
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.